Introduction: Salvage treatment for acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor in patients with non-small-cell lung cancer is a matter of clinical concern. Several retrospective reports have indicated the usefulness of epidermal growth factor receptor tyrosine kinase inhibitor readministration; however, there have been few prospective studies.
Materials And Methods: This study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced or metastatic non-small-cell lung cancer who responded well to initial gefitinib treatment. The subjects received at least 1 regimen of cytotoxic chemotherapy after progressive disease with the initial gefitinib therapy. Gefitinib administration (250 mg/d, orally) was started after progressive disease with the previous chemotherapeutic regimen. The primary endpoint in the present study was the response rate.
Results: Twenty patients were enrolled between April 2007 and May 2011. Three patients achieved partial response, and 6 showed stable disease. Thus, the overall response rate and disease control rate of gefitinib readministration were 15% (95% CI, 3.21-37.9) and 45% (95% CI, 23.1-68.5), respectively. Median progression-free survival and overall survival from the start of gefitinib readministration were 2.0 months (95% CI, 0.9-3.1 months) and 12.0 months (95% CI, 8.0-16.0 months), respectively.
Conclusion: These results suggest that gefitinib readministration may be an option, albeit with a low response rate and short progression-free survival, for patients who responded well to initial gefitinib followed by systemic chemotherapy. These findings provide valuable information for the management of previous gefitinib responders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cllc.2012.01.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005).
Lung
February 2024
Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
Purpose: This study investigated the safety and efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) re-administration after recovery from EGFR-TKI-induced interstitial lung disease (ILD).
Methods: This multicenter retrospective study collected data from consecutive advanced NSCLC patients who underwent EGFR-TKI re-administration after recovery from EGFR-TKI-induced ILD.
Results: Fifty-eight patients were registered.
EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy.
Invest New Drugs
December 2022
Department of Thoracic Medical Oncology, the Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Article Synopsis
- Data on re-administering EGFR-TKIs after osimertinib failure in patients with T790M-positive NSCLC is scarce and efficacy can vary based on T790M mutation status.
- A study looked at 28 patients who received EGFR-TKI re-administration, out of which 17 had repeat biopsies to analyze their T790M status before treatment.
- The results showed a 31% overall response rate (ORR) and 54% disease control rate (DCR) in the T790M loss group, indicating that re-administration may be more effective in patients with T790M loss compared to the general population.
Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report.
Ann Palliat Med
July 2021
Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Although tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have a favorable and durable treatment response, almost all patients will eventually acquire resistance and develop disease progression. Re-administration of first and second-generation EGFR TKIs has been successfully executed in advanced non-small cell lung cancer (NSCLC) subsequent to EGFR-TKI resistance. However, osimertinib rechallenge following osimertinib resistance in EGFR T790M-negative patient is less explored.
View Article and Find Full Text PDFContinued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive mutations.
J Int Med Res
October 2020
Department of Oncology, the People's Hospital of Bishan District, Bishan, Chongqing, China.
Purpose: To evaluate the effectiveness and safety of gefitinib retreatment beyond disease progression in patients with advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor () mutations.
Methods: Data from patients with stage III/IV NSCLC were analyzed retrospectively. Patients with sensitive mutations received first-line treatment with gefitinib followed by retreatment with gefitinib after disease progression.
Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants.
J Thorac Dis
August 2020
Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Article Synopsis
- - The study aimed to estimate how common and what factors contribute to fatal toxic effects from epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell lung cancer (NSCLC).
- - Researchers reviewed 53 clinical trials with nearly 10,000 participants, finding that 1.33% experienced fatal toxic effects, particularly noting higher incidences in Japanese patients and those undergoing first-line treatments.
- - The most frequent cause of these fatalities was interstitial lung disease (ILD), followed by pneumonia, respiratory failure, and diarrhea, highlighting the need for better risk assessment in specific patient populations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!